Markets
AZTR

Azitra's ATR-04 Gets FDA Fast Track Designation For Skin Rash Linked To EGFR Inhibitors

September 18, 2024 — 10:32 am EDT

Written by RTTNews.com for RTTNews->

(RTTNews) - Azitra, Inc. (AZTR) Wednesday announced the receipt of Fast Track Designation from the FDA for ATR-04, a topical treatment targeting moderate to severe skin rash linked to Epidermal Growth Factor Receptor inhibitors or EGFRi, and their associated dermal toxicity.

ATR-04 is a live biotherapeutic product featuring an engineered strain of Staphylococcus epidermidis.

Azitra intends to begin a Phase 1/2 clinical trial involving patients with skin toxicity from EGFR inhibitors by the end of 2024.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

Markets
RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source->

Stocks mentioned

AZTR

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

  • •

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.